Lloyd Segal

Job Title: President & CEO
Company: Repare Therapeutics

Lloyd is the President & CEO of Repare Therapeutics (Nasdaq: RPTX), a leading clinical stage precision oncology company.

Prior to Repare, Lloyd was a Managing Partner with Persistence Capital Partners. He began his career with McKinsey & Company, and subsequently served as CEO of several emerging biotechnology companies including Advanced Bioconcept Inc., Caprion Pharmaceuticals Inc. and Thallion Pharmaceuticals Inc.

He currently serves on the board of directors of Aktis Oncology (private) and the GBC American Fund. Lloyd previously served as Chairman of LMC Diabetes & Endocrinology and was Chairman of the Board of MedReleaf (TMX: LEAF), which was sold to Aurora Cannabis for $3.2 billion in 2018. He served as Entrepreneur-in-Residence with Versant Ventures from 2016 to 2020.

Lloyd was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies.

Lloyd holds a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School.